In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix (OCUL – Research Report), with a price target of $15.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Yi Chen has given his Buy rating due to a combination of factors surrounding Ocular Therapeutix’s ongoing clinical trials and their potential impact on the company’s future. The SOL-R trial, which is nearing completion of enrollment, is a significant step forward for the company as it aims to support a New Drug Application (NDA) for AXPAXLI in treating wet AMD. The trial’s robust design, including a high retention rate and adherence to protocol, reflects strong interest from both patients and healthcare providers.
Furthermore, the SOL-R trial is designed to demonstrate non-inferiority of AXPAXLI compared to aflibercept, with the potential for a dosing schedule that could offer a competitive advantage. The complementary SOL-1 trial is also progressing well, with topline results expected in early 2026, and its incorporation of re-dosing could expedite the NDA process. These factors, combined with the potential for a superior treatment option, underpin Yi Chen’s confidence in the company’s prospects and justify the Buy rating with a price target of $15.
According to TipRanks, Chen is an analyst with an average return of -13.3% and a 31.84% success rate. Chen covers the Healthcare sector, focusing on stocks such as Vivani Medical, Opko Health, and Clearside Biomedical.
In another report released today, Scotiabank also maintained a Buy rating on the stock with a $22.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue